Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
PULSE BIOSCIENCES, INC. terminated Prior Distribution Agreement with the sales agents named therein valued at up to $59,976,196 (effective 2026-02-18).
- Action
- termination
- Agreement
- atm program
- Counterparty
- the sales agents named therein
- Value
- up to $59,976,196
- Effective
- 2026-02-18
Exact text from the filing
Prior to the Company’s entry into the Sales Agreement, on February 18, 2026, the Company terminated its at-the-market offering program in accordance with the terms of its prior equity distribution agreement, dated as of July 15, 2024 (the “Prior Distribution Agreement”), between the Company and the sales agents named therein.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
PULSE BIOSCIENCES, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $59,976,196 (effective 2026-02-19).
- Action
- entry
- Agreement
- atm program
- Counterparty
- TD Securities (USA) LLC
- Value
- up to $59,976,196
- Effective
- 2026-02-19
Exact text from the filing
On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through TD Cowen shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $59,976,196 (the “Shares”).
View on SEC.gov